ClinicalTrials.gg
CompletedNCT04662710Updated Apr 28, 2026Results posted

Efficacy and Safety of Lenvatinib (E7080/MK-7902) Plus Pembrolizumab (MK-3475) Plus Chemotherapy in Participants With Advanced/Metastatic Gastroesophageal Adenocarcinoma (MK-7902-015/E7080-G000-321/LEAP-015)

A Phase 3 interventional study of Pembrolizumab and Lenvatinib in Advanced/Metastatic Gastroesophageal Adenocarcinoma, sponsored by Merck Sharp & Dohme LLC. Completed at 177 sites in 24 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-04-28.

Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
895
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

The purpose of this study is to assess the efficacy and safety of lenvatinib (E7080/MK-7902) plus pembrolizumab (MK-3475) plus chemotherapy compared with chemotherapy alone in participants with advanced/metastatic gastroesophageal cancer.

The primary study hypotheses are that lenvatinib plus pembrolizumab plus chemotherapy is superior to chemotherapy alone for both overall survival (OS) and progression-free survival (PFS) per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1) as assessed by blinded independent central review (BICR), in participants with programmed cell death-ligand 1 (PD-L1) Combined Positive Score (CPS) ≥1 and in all participants.

Read the detailed description

There will be 2 parts to the study: a Safety Run-in (Part 1) and the Main Study (Part 2). In Part 1 (Safety Run-in), approximately 12 participants will be treated with lenvatinib in combination with pembrolizumab and chemotherapy with either capecitabine and oxaliplatin (CAPOX), or 5-fluorouracil (5-FU), Leucovorin, and oxaliplatin (mFOLFOX6). Participants will be closely followed for dose-limiting toxicities for 21 days after the first dose of study intervention.

In Part 2, up to 878 eligible participants (not including those participating in Part 1) will be randomly assigned in a 1:1 ratio to either lenvatinib plus pembrolizumab plus chemotherapy (CAPOX or mFOLFOX6) or Chemotherapy alone (CAPOX or mFOLFOX6).

Participants can receive up to 18 infusions (up to 2 years) of pembrolizumab in the first course. Participants may be eligible to receive a second course of pembrolizumab (approximately 1 year) at the investigator's discretion.

As of Amendment 8 (Effective 06/10/2025), Second Course will no longer be offered. Any participant currently receiving Second Course retreatment will be able to continue treatment as planned. Imaging will be performed per local standard of care.

02

Conditions studied

  • Advanced/Metastatic Gastroesophageal Adenocarcinoma

Keywords

  • Programmed Cell Death-1 (PD1, PD-1)
  • Programmed Death-Ligand 1 (PDL1, PD-L1)
03

In context

Lead sponsor

Merck Sharp & Dohme LLC is the lead sponsor of 2,167 studies on the registry; 132 are open to participants now.

Of its 504 completed or terminated interventional studies of FDA-regulated products, 371 (74%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Has and/or cytologically confirmed diagnosis of previously untreated, locally advanced unresectable or gastroesophageal adenocarcinoma
  • Is not expected to require tumor resection during the treatment course
  • Has gastroesophageal adenocarcinoma that is not human epidermal growth factor receptor 2 ()/neu positive
  • Has as defined by (RECIST) 1.1 by scan with IV contrast as determined by the local site investigator
  • Male participants agree to refrain from donating sperm and agree to either remain abstinent from heterosexual intercourse as their preferred and usual lifestyle OR agree to use , during the intervention period and for ≥7 days after last dose of lenvatinib or 90 days after last dose of chemotherapy-whichever comes last
  • Female participants not pregnant or breastfeeding are eligible to participate if not a women of (WOCBP), or if a WOCBP they either use a contraceptive method that is highly effective OR remain abstinent from heterosexual intercourse as their preferred and usual lifestyle, and do not donate eggs (ova, oocytes) to others or freeze/store for their own use, and abstain from breastfeeding during the intervention period through 120 days after last dose of pembrolizumab, 30 days after last dose of lenvatinib, or 180 days after last dose of chemotherapy-whichever occurs last
  • Has a performance status of 0 or 1 on the (ECOG) Performance Scale within 3 days prior to the first dose of study treatment
  • Has adequately controlled blood pressure with or without antihypertensive medications
  • Has adequate organ function

Exclusion criteria

Exclusion Criteria:

  • Has had previous therapy for locally advanced unresectable or gastric/gastroesophageal junction (GEJ) esophageal adenocarcinoma
  • Has had major surgery within 28 days prior to first dose of study interventions
  • Has had radiotherapy within 14 days of randomization
  • Has a known additional that is progressing or has required active treatment within the past 5 years
  • Has known central nervous system (CNS) metastases and/or carcinomatous meningitis
  • Has severe (≥Grade 3) to treatment with an monoclonal antibody (mAb) or known sensitivity or intolerance to any component of lenvatinib, pembrolizumab, study chemotherapy agents and/or to any , murine proteins, or platinum containing products
  • Has had an allogeneic tissue/solid organ transplant
  • Has perforation risks or significant gastrointestinal (GI) bleeding
  • Has GI obstruction, poor oral intake (CAPOX participants), or difficulty in taking oral medication (CAPOX participants)
  • Has received prior therapy with an anti-programmed cell death 1 (), anti-PD-L1, or anti-PD-L2 agent or with an agent directed to another stimulatory or coinhibitory T-cell receptor
  • Has received prior therapy with anti- vascular endothelial growth factor (VEGF) tyrosine kinase inhibitor or anti-VEGF mAb
  • Has received a live or within 30 days before the first dose of study drug
  • Has an active disease that has required systemic treatment in past 2 years (i.e., with use of disease modifying agents, or drugs)
  • Has radiographic evidence of encasement or invasion of a major blood vessel, or of intratumoral cavitation
  • Has inadequate cardiac function
  • Has a history of (noninfectious) pneumonitis/interstitial lung disease that required steroids or has current pneumonitis/interstitial lung disease
  • Has poorly controlled diarrhea
  • Has accumulation of pleural, ascitic, or pericardial fluid requiring drainage or diuretic drugs within 2 weeks prior to enrollment
  • Has peripheral neuropathy ≥Grade 2
  • Has a known history of (HIV) or HIV 1/2 antibodies
  • Has a known history of (defined as HBsAg reactive) or known active virus (defined as HCV ribonucleic acid (RNA) [qualitative] is detected) infection
  • Has weight loss of >20% within the last 3 months
Terms in these criteria, in plain language(19)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
895 participants (actual)

Study arms

  • Experimental
    Lenvatinib + Pembrolizumab + Chemotherapy

    Participants receive lenvatinib administered orally (PO) every day (QD) in combination with pembrolizumab intravenously (IV) every 6 weeks (Q6W) plus chemotherapy with either capecitabine and oxaliplatin (CAPOX) or chemotherapy with 5-FU, leucovorin, and oxaliplatin (mFOLFOX6). Induction with lenvatinib 8 mg QD plus pembrolizumab (400 mg Q6W) plus chemotherapy (CAPOX or mFOLFOX6) will be administered for 2 cycles (approximately 12 weeks), followed by consolidation with lenvatinib 20 mg QD plus pembrolizumab (400 mg Q6W) for 16 cycles. A cycle is 6 weeks (42 days).

    Biological: Pembrolizumab · Biological: Lenvatinib · Drug: Oxaliplatin · Drug: Capecitabine · Drug: Leucovorin (or Levoleucovorin) · Drug: 5-FU

  • Experimental
    Chemotherapy

    Participants receive chemotherapy with either CAPOX Q3W or mFOLFOX6 Q2W. A cycle is 6 weeks (42 days).

    Drug: Oxaliplatin · Drug: Capecitabine · Drug: Leucovorin (or Levoleucovorin) · Drug: 5-FU

Interventions

  • BiologicalPembrolizumab

    400 mg Q6W by IV infusion

    Also known as: MK-3475, Keytruda®

  • BiologicalLenvatinib

    Administered PO QD, 8 mg induction/20 mg consolidation.

    Also known as: MK-7902, E7080

  • 130 mg/m\^2 administered by IV infusion on Day 1 of Weeks 1 and 4 of each Q6W cycle as part of CAPOX chemotherapy, or 85 mg/m\^2 administered by IV infusion on Day 1 and Week 1, 3 and 5 of each Q6W cycle as part of mFOLFOX6 chemotherapy.

  • 1000 mg/m\^2 administered PO twice daily (BID) on Days 1-14, 22-35 of each Q6W cycle as part of CAPOX chemotherapy.

  • Administered by IV infusion at 400 mg/m\^2 (leucovorin) or 200 mg/m\^2 (levoleucovorin) on Day 1, and Week 1, 3 and 5 of each Q6W cycle as part of mFOLFOX6 chemotherapy.

  • Drug5-FU

    400 mg/m\^2 bolus IV infusion followed by 2400 mg/m\^2 continuous IV infusion administered on Day 1, and Week 1, 3, 5, of each Q2W cycle as part of mFOLFOX6 chemotherapy.

06

What researchers measure

Primary outcomes

  1. Part 1: Number of Participants With Dose Limiting Toxicities (DLTs)

    A DLT was defined as a specific adverse event graded for toxicity using the Common Terminology Criteria for Adverse Events (CTCAE) v5.0. Hematologic DLTs included Grade 4 neutropenia lasting for ≥7 days, Grade 3 or Grade 4 febrile neutropenia, Grade 3 thrombocytopenia with bleeding, Grade 4 thrombocytopenia, or Grade 4 anemia. Nonhematologic DLTs included any other Grade 4 or Grade 5 toxicity, Grade 3 toxicities lasting \>3 days (excluding nausea, vomiting, and diarrhea controlled by medical intervention within 72 hours, and Grade 3 rash in the absence of desquamation with no mucosal involvement), Grade 3 hypertension not able to be controlled by medication, ≥ Grade 3 gastrointestinal perforation, ≥Grade 3 wound dehiscence requiring medical or surgical intervention, any grade thromboembolic event, or any Grade 3 nonhematologic laboratory value if medical intervention was required or the abnormality led to hospitalization. The number of participants in Part 1 with DLTs is reported.

    Time frame: Up to ~21 days

  2. Part 1: Number of Participants With Adverse Events (AEs)

    An AE is any untoward medical occurrence in a participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. The number of participants in Part 1 with AEs is reported

    Time frame: Up to ~44 months

  3. Part 1: Number of Participants Who Discontinued Study Treatment Due to an AE

    An AE is any untoward medical occurrence in a participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. The number of participants in Part 1 that discontinued study treatment due to an AE is reported.

    Time frame: Up to ~29 months

  4. Part 2: Overall Survival (OS) in Participants With Programmed Cell Death Ligand 1 (PD-L1) Combined Positive Score (CPS) ≥1

    OS is defined as the time from randomization to death due to any cause. OS is reported by treatment arm for PD-L1 CPS ≥1 participants in Part 2.

    Time frame: Up to ~41 months

  5. Part 2: OS in All Participants

    OS is defined as the time from randomization to death due to any cause. OS is reported by treatment arm for all participants in Part 2.

    Time frame: Up to ~41 months

  6. Part 2: Progression-Free Survival (PFS) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as Assessed by Blinded Independent Central Review (BICR) in Participants With PD-L1 CPS ≥1

    PFS is defined as the time from randomization to the first documented progressive disease (PD) per RECIST 1.1 by BICR or death from any cause, whichever occurs first. Per RECIST 1.1 modified to follow a maximum of 10 target lesions and a maximum of 5 target lesions per organ, PD is defined as at least a 20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. The appearance of one or more new lesions is also considered PD. PFS is reported by treatment arm for PD-L1 CPS ≥1 participants in Part 2.

    Time frame: Up to ~29 months

  7. Part 2: PFS Per RECIST 1.1 as Assessed by BICR in All Participants

    PFS is defined as the time from randomization to the first documented PD per RECIST 1.1 by BICR or death from any cause, whichever occurs first. Per RECIST 1.1 modified to follow a maximum of 10 target lesions and a maximum of 5 target lesions per organ, PD is defined as at least a 20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. The appearance of one or more new lesions is also considered PD. PFS is reported by treatment arm for all participants in Part 2.

    Time frame: Up to ~29 months

Secondary outcomes

  1. Part 2: Objective Response Rate (ORR) Per RECIST 1.1 as Assessed by BICR in Participants With PD-L1 CPS ≥1

    ORR is defined as the percentage of participants in the analysis population who have a Complete Response (CR: disappearance of all target lesions) or a Partial Response (PR: at least a 30% decrease in the sum of diameters of target lesions) per RECIST 1.1 modified to follow a maximum of 10 target lesions and a maximum of 5 target lesions per organ, and assessed by BICR. ORR is reported by treatment arm for PD-L1 CPS ≥1 participants in Part 2.

    Time frame: Up to ~29 months

  2. Part 2: ORR Per RECIST 1.1 as Assessed by BICR in All Participants

    ORR is defined as the percentage of participants in the analysis population who have a CR (disappearance of all target lesions) or a PR (at least a 30% decrease in the sum of diameters of target lesions) per RECIST 1.1 modified to follow a maximum of 10 target lesions and a maximum of 5 target lesions per organ, and assessed by BICR. ORR is reported by treatment arm for all participants in Part 2.

    Time frame: Up to ~29 months

  3. Part 2: Duration of Response (DOR) Per RECIST 1.1 as Assessed by BICR in Participants With PD-L1 CPS ≥1

    For participants who demonstrated confirmed CR or PR, DOR is defined as the time from the first CR (disappearance of all target lesions) or PR (at least a 30% decrease in the sum of diameters of target lesions) to subsequent PD or death due to any cause, whichever occurs first. Per RECIST 1.1 modified to follow a maximum of 10 target lesions and a maximum of 5 target lesions per organ, PD is defined as at least a 20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. The appearance of one or more new lesions is also considered PD. DOR is reported by treatment arm for PD-L1 CPS ≥1 participants in Part 2.

    Time frame: Up to ~41 months

  4. Part 2: DOR Per RECIST 1.1 as Assessed by BICR in All Participants

    For participants who demonstrated confirmed CR or PR, DOR is defined as the time from the first CR (disappearance of all target lesions) or PR (at least a 30% decrease in the sum of diameters of target lesions) to subsequent PD or death due to any cause, whichever occurs first. Per RECIST 1.1 modified to follow a maximum of 10 target lesions and a maximum of 5 target lesions per organ, PD is defined as at least a 20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. The appearance of one or more new lesions is also considered PD. DOR is reported by treatment arm for all participants in Part 2.

    Time frame: Up to ~41 months

  5. Part 2: Number of Participants With AEs

    An AE is any untoward medical occurrence in a participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. The number of participants in Part 2 with AEs is reported by treatment arm.

    Time frame: Up to ~41 months

  6. Part 2: Number of Participants Who Discontinued Study Treatment Due to an AE

    An AE is any untoward medical occurrence in a participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. The number of participants in Part 2 that discontinued study treatment due to an AE is reported by treatment arm.

    Time frame: Up to ~41 months

07

Results

Posted Nov 28, 2025

Participant flow

Participant flow — Overall Study
MilestonePart 1 : Lenvatinib + Pembrolizumab + ChemotherapyPart 2: Lenvatinib + Pembrolizumab + ChemotherapyPart 2: Chemotherapy
Started15443437
Treated15441429
Received second course of pembrolizumab +/- lenvatinib130
Completed000
Not completed15443437
Withdrew: Death14331367
Withdrew: Ongoing110956
Withdrew: Withdrawal by subject0314

Outcome measures

PrimaryPart 1: Number of Participants With Dose Limiting Toxicities (DLTs)

A DLT was defined as a specific adverse event graded for toxicity using the Common Terminology Criteria for Adverse Events (CTCAE) v5.0. Hematologic DLTs included Grade 4 neutropenia lasting for ≥7 days, Grade 3 or Grade 4 febrile neutropenia, Grade 3 thrombocytopenia with bleeding, Grade 4 thrombocytopenia, or Grade 4 anemia. Nonhematologic DLTs included any other Grade 4 or Grade 5 toxicity, Grade 3 toxicities lasting \>3 days (excluding nausea, vomiting, and diarrhea controlled by medical intervention within 72 hours, and Grade 3 rash in the absence of desquamation with no mucosal involvement), Grade 3 hypertension not able to be controlled by medication, ≥ Grade 3 gastrointestinal perforation, ≥Grade 3 wound dehiscence requiring medical or surgical intervention, any grade thromboembolic event, or any Grade 3 nonhematologic laboratory value if medical intervention was required or the abnormality led to hospitalization. The number of participants in Part 1 with DLTs is reported.

Time frame:
Up to ~21 days
Reported as:
Count of participants · Participants
Part 1: Number of Participants With Dose Limiting Toxicities (DLTs)
ParticipantsPart 1 : Lenvatinib + Pembrolizumab + ChemotherapyPart 2: Lenvatinib + Pembrolizumab + ChemotherapyPart 2: Chemotherapy
Part 1: Number of Participants With Dose Limiting Toxicities (DLTs)2——
PrimaryPart 1: Number of Participants With Adverse Events (AEs)

An AE is any untoward medical occurrence in a participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. The number of participants in Part 1 with AEs is reported

Time frame:
Up to ~44 months
Reported as:
Count of participants · Participants
Part 1: Number of Participants With Adverse Events (AEs)
ParticipantsSafety Run-In: Lenvatinib + Pembrolizumab + ChemotherapyPart 2: Lenvatinib + Pembrolizumab + ChemotherapyPart 2: Chemotherapy
Part 1: Number of Participants With Adverse Events (AEs)15——
PrimaryPart 1: Number of Participants Who Discontinued Study Treatment Due to an AE

An AE is any untoward medical occurrence in a participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. The number of participants in Part 1 that discontinued study treatment due to an AE is reported.

Time frame:
Up to ~29 months
Reported as:
Count of participants · Participants
Part 1: Number of Participants Who Discontinued Study Treatment Due to an AE
ParticipantsSafety Run-In: Lenvatinib + Pembrolizumab + ChemotherapyPart 2: Lenvatinib + Pembrolizumab + ChemotherapyPart 2: Chemotherapy
Part 1: Number of Participants Who Discontinued Study Treatment Due to an AE5——
PrimaryPart 2: Overall Survival (OS) in Participants With Programmed Cell Death Ligand 1 (PD-L1) Combined Positive Score (CPS) ≥1

OS is defined as the time from randomization to death due to any cause. OS is reported by treatment arm for PD-L1 CPS ≥1 participants in Part 2.

Time frame:
Up to ~41 months
Reported as:
Median · Months
Part 2: Overall Survival (OS) in Participants With Programmed Cell Death Ligand 1 (PD-L1) Combined Positive Score (CPS) ≥1
MonthsPart 2: Lenvatinib + Pembrolizumab + ChemotherapyPart 2: Chemotherapy
Part 2: Overall Survival (OS) in Participants With Programmed Cell Death Ligand 1 (PD-L1) Combined Positive Score (CPS) ≥112.6 (10.6 to 14.2)12.9 (11.6 to 14.6)
Statistical analysis
  • Part 2: Lenvatinib + Pembrolizumab + Chemotherapy vs Part 2: Chemotherapy · Log Rank · p = .0244 (One-sided p-value based on log-rank test stratified by region, ECOG performance status, and chemotherapy type) · Hazard ratio (hr): 0.84 · 95% CI 0.71 to 1.00HR based on Cox regression model with Efron's method of tie handling with treatment as a covariate stratified by region, ECOG performance status, and chemotherapy type
PrimaryPart 2: OS in All Participants

OS is defined as the time from randomization to death due to any cause. OS is reported by treatment arm for all participants in Part 2.

Time frame:
Up to ~41 months
Reported as:
Median · Months
Part 2: OS in All Participants
MonthsPart 2: Lenvatinib + Pembrolizumab + ChemotherapyPart 2: Chemotherapy
Part 2: OS in All Participants13.1 (11.6 to 14.3)13.0 (11.6 to 14.7)
Statistical analysis
  • Part 2: Lenvatinib + Pembrolizumab + Chemotherapy vs Part 2: Chemotherapy · Log Rank · p = 0.0330 (One-sided p-value based on log-rank test stratified by region, ECOG performance status and chemotherapy type.) · Hazard ratio (hr): 0.87 · 95% CI 0.75 to 1.01HR based on Cox regression model with Efron's method of tie handling with treatment as a covariate stratified by region, ECOG performance status, and chemotherapy
PrimaryPart 2: Progression-Free Survival (PFS) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as Assessed by Blinded Independent Central Review (BICR) in Participants With PD-L1 CPS ≥1

PFS is defined as the time from randomization to the first documented progressive disease (PD) per RECIST 1.1 by BICR or death from any cause, whichever occurs first. Per RECIST 1.1 modified to follow a maximum of 10 target lesions and a maximum of 5 target lesions per organ, PD is defined as at least a 20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. The appearance of one or more new lesions is also considered PD. PFS is reported by treatment arm for PD-L1 CPS ≥1 participants in Part 2.

Time frame:
Up to ~29 months
Reported as:
Median · Months
Part 2: Progression-Free Survival (PFS) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as Assessed by Blinded Independent Central Review (BICR) in Participants With PD-L1 CPS ≥1
MonthsPart 2: Lenvatinib + Pembrolizumab + ChemotherapyPart 2: Chemotherapy
Part 2: Progression-Free Survival (PFS) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as Assessed by Blinded Independent Central Review (BICR) in Participants With PD-L1 CPS ≥17.3 (6.8 to 8.3)6.9 (5.8 to 7.2)
Statistical analysis
  • Part 2: Lenvatinib + Pembrolizumab + Chemotherapy vs Part 2: Chemotherapy · Log Rank · p = .0012 (One-sided p-value based on log-rank test stratified by region, performance status, and chemotherapy type) · Hazard ratio (hr): 0.75 · 95% CI 0.62 to 0.90HR Based on Cox regression model with Efron's method of tie handling with treatment as a covariate stratified by region, ECOG performance status, and chemotherapy type.
PrimaryPart 2: PFS Per RECIST 1.1 as Assessed by BICR in All Participants

PFS is defined as the time from randomization to the first documented PD per RECIST 1.1 by BICR or death from any cause, whichever occurs first. Per RECIST 1.1 modified to follow a maximum of 10 target lesions and a maximum of 5 target lesions per organ, PD is defined as at least a 20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. The appearance of one or more new lesions is also considered PD. PFS is reported by treatment arm for all participants in Part 2.

Time frame:
Up to ~29 months
Reported as:
Median · Months
Part 2: PFS Per RECIST 1.1 as Assessed by BICR in All Participants
MonthsPart 2: Lenvatinib + Pembrolizumab + ChemotherapyPart 2: Chemotherapy
Part 2: PFS Per RECIST 1.1 as Assessed by BICR in All Participants7.2 (6.8 to 8.3)7.0 (6.4 to 7.5)
Statistical analysis
  • Part 2: Lenvatinib + Pembrolizumab + Chemotherapy vs Part 2: Chemotherapy · Log Rank · p = 0.0019 (One-sided p-value based on log-rank test stratified by region, ECOG performance status, and chemotherapy type.) · Hazard ratio (hr): 0.78 · 95% CI 0.66 to 0.92HR based on Cox regression model with Efron's method of tie handling with treatment as a covariate stratified by region, ECOG performance status, and chemotherapy type.
SecondaryPart 2: Objective Response Rate (ORR) Per RECIST 1.1 as Assessed by BICR in Participants With PD-L1 CPS ≥1

ORR is defined as the percentage of participants in the analysis population who have a Complete Response (CR: disappearance of all target lesions) or a Partial Response (PR: at least a 30% decrease in the sum of diameters of target lesions) per RECIST 1.1 modified to follow a maximum of 10 target lesions and a maximum of 5 target lesions per organ, and assessed by BICR. ORR is reported by treatment arm for PD-L1 CPS ≥1 participants in Part 2.

Time frame:
Up to ~29 months
Reported as:
Number · Percentage of Participants
Part 2: Objective Response Rate (ORR) Per RECIST 1.1 as Assessed by BICR in Participants With PD-L1 CPS ≥1
Percentage of ParticipantsPart 2: Lenvatinib + Pembrolizumab + ChemotherapyPart 2: Chemotherapy
Part 2: Objective Response Rate (ORR) Per RECIST 1.1 as Assessed by BICR in Participants With PD-L1 CPS ≥159.5 (54.0 to 64.8)45.4 (40.1 to 50.7)
Statistical analysis
  • Part 2: Lenvatinib + Pembrolizumab + Chemotherapy vs Part 2: Chemotherapy · t-test, 1 sided · p = <0.0001 · Difference in percentage: 14.3 · 95% CI 6.9 to 21.5
SecondaryPart 2: ORR Per RECIST 1.1 as Assessed by BICR in All Participants

ORR is defined as the percentage of participants in the analysis population who have a CR (disappearance of all target lesions) or a PR (at least a 30% decrease in the sum of diameters of target lesions) per RECIST 1.1 modified to follow a maximum of 10 target lesions and a maximum of 5 target lesions per organ, and assessed by BICR. ORR is reported by treatment arm for all participants in Part 2.

Time frame:
Up to ~29 months
Reported as:
Number · Percentage of Participants
Part 2: ORR Per RECIST 1.1 as Assessed by BICR in All Participants
Percentage of ParticipantsPart 2: Lenvatinib + Pembrolizumab + ChemotherapyPart 2: Chemotherapy
Part 2: ORR Per RECIST 1.1 as Assessed by BICR in All Participants58.0 (53.3 to 62.7)43.9 (39.2 to 48.7)
Statistical analysis
  • Part 2: Lenvatinib + Pembrolizumab + Chemotherapy vs Part 2: Chemotherapy · t-test, 1 sided · p = <0.0001 · Difference in percentage: 14.2 · 95% CI 7.7 to 20.6
SecondaryPart 2: Duration of Response (DOR) Per RECIST 1.1 as Assessed by BICR in Participants With PD-L1 CPS ≥1

For participants who demonstrated confirmed CR or PR, DOR is defined as the time from the first CR (disappearance of all target lesions) or PR (at least a 30% decrease in the sum of diameters of target lesions) to subsequent PD or death due to any cause, whichever occurs first. Per RECIST 1.1 modified to follow a maximum of 10 target lesions and a maximum of 5 target lesions per organ, PD is defined as at least a 20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. The appearance of one or more new lesions is also considered PD. DOR is reported by treatment arm for PD-L1 CPS ≥1 participants in Part 2.

Time frame:
Up to ~41 months
Reported as:
Median · Months
Part 2: Duration of Response (DOR) Per RECIST 1.1 as Assessed by BICR in Participants With PD-L1 CPS ≥1
MonthsPart 2: Lenvatinib + Pembrolizumab + ChemotherapyPart 2: Chemotherapy
Part 2: Duration of Response (DOR) Per RECIST 1.1 as Assessed by BICR in Participants With PD-L1 CPS ≥18.5 (7.1 to 12.5)6.5 (5.6 to 7.0)
SecondaryPart 2: DOR Per RECIST 1.1 as Assessed by BICR in All Participants

For participants who demonstrated confirmed CR or PR, DOR is defined as the time from the first CR (disappearance of all target lesions) or PR (at least a 30% decrease in the sum of diameters of target lesions) to subsequent PD or death due to any cause, whichever occurs first. Per RECIST 1.1 modified to follow a maximum of 10 target lesions and a maximum of 5 target lesions per organ, PD is defined as at least a 20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. The appearance of one or more new lesions is also considered PD. DOR is reported by treatment arm for all participants in Part 2.

Time frame:
Up to ~41 months
Reported as:
Median · Months
Part 2: DOR Per RECIST 1.1 as Assessed by BICR in All Participants
MonthsPart 2: Lenvatinib + Pembrolizumab + ChemotherapyPart 2: Chemotherapy
Part 2: DOR Per RECIST 1.1 as Assessed by BICR in All Participants8.6 (7.3 to 12.4)6.7 (5.6 to 7.7)
SecondaryPart 2: Number of Participants With AEs

An AE is any untoward medical occurrence in a participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. The number of participants in Part 2 with AEs is reported by treatment arm.

Time frame:
Up to ~41 months

Results for this outcome have not been posted.

SecondaryPart 2: Number of Participants Who Discontinued Study Treatment Due to an AE

An AE is any untoward medical occurrence in a participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. The number of participants in Part 2 that discontinued study treatment due to an AE is reported by treatment arm.

Time frame:
Up to ~41 months

Results for this outcome have not been posted.

Adverse events

Collected over Up to approximately 44 months. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Part 1: Lenvatinib + Pembrolizumab + Chemotherapy First Course13/15 (86.7%)6/15 (40%)14/15 (93.3%)
Part 2: Lenvatinib + Pembrolizumab + Chemotherapy First Course333/443 (75.2%)226/441 (51.2%)435/441 (98.6%)
Chemotherapy First Course374/437 (85.6%)137/429 (31.9%)406/429 (94.6%)
Part 1: Pembrolizumab +/-Lenvatinib Second Course1/1 (100%)0/1 (0%)0/1 (0%)
Part 2: Pembrolizumab +/-Lenvatinib Second Course0/3 (0%)1/3 (33.3%)1/3 (33.3%)
Most frequent serious events
Showing 10 of 233
Most frequent serious events
EventPart 1: Lenvatinib + Pembrolizumab + Chemotherapy First CoursePart 2: Lenvatinib + Pembrolizumab + Chemotherapy First CourseChemotherapy First CoursePart 1: Pembrolizumab +/-Lenvatinib Second CoursePart 2: Pembrolizumab +/-Lenvatinib Second Course
NauseaGastrointestinal disorders0/156/4412/4290/11/3
VomitingGastrointestinal disorders0/1510/4417/4290/11/3
AnaemiaBlood and lymphatic system disorders1/153/4413/4290/10/3
Atrial thrombosisCardiac disorders1/150/4410/4290/10/3
Abdominal pain upperGastrointestinal disorders1/150/4411/4290/10/3
Gastric perforationGastrointestinal disorders1/157/4410/4290/10/3
Intestinal obstructionGastrointestinal disorders1/153/44111/4290/10/3
Liver injuryHepatobiliary disorders1/150/4411/4290/10/3
PneumoniaInfections and infestations1/154/44110/4290/10/3
DiarrhoeaGastrointestinal disorders0/1513/4414/4290/10/3
Most frequent other events
Showing 10 of 101
Most frequent other events
EventPart 1: Lenvatinib + Pembrolizumab + Chemotherapy First CoursePart 2: Lenvatinib + Pembrolizumab + Chemotherapy First CourseChemotherapy First CoursePart 1: Pembrolizumab +/-Lenvatinib Second CoursePart 2: Pembrolizumab +/-Lenvatinib Second Course
NauseaGastrointestinal disorders8/15196/441193/4290/10/3
Neutrophil count decreasedInvestigations7/15209/441195/4290/10/3
DiarrhoeaGastrointestinal disorders7/15201/441123/4290/10/3
VomitingGastrointestinal disorders7/15110/441105/4290/10/3
Platelet count decreasedInvestigations2/15129/441180/4290/10/3
Palmar-plantar erythrodysaesthesia syndromeSkin and subcutaneous tissue disorders6/1597/44160/4290/10/3
Decreased appetiteMetabolism and nutrition disorders5/15173/441117/4290/10/3
AnaemiaBlood and lymphatic system disorders2/15159/441161/4290/10/3
Weight decreasedInvestigations1/15148/44196/4290/10/3
DyspepsiaGastrointestinal disorders0/1522/44119/4290/11/3

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Part 1: Lenvatinib +Pembrolizumab + ChemotherapyPart 2: Lenvatinib + Pembrolizumab + ChemotherapyPart 2: ChemotherapyTotal
Mean55.9 ± 59.759.7 ± 12.559.1 ± 12.059.3 ± 12.3
Sex: Female, Male
Sex: Female, Male(Participants)Part 1: Lenvatinib +Pembrolizumab + ChemotherapyPart 2: Lenvatinib + Pembrolizumab + ChemotherapyPart 2: ChemotherapyTotal
Female8151131290
Male7292306605
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Part 1: Lenvatinib +Pembrolizumab + ChemotherapyPart 2: Lenvatinib + Pembrolizumab + ChemotherapyPart 2: ChemotherapyTotal
Hispanic or Latino7116115238
Not Hispanic or Latino8319313640
Unknown or Not Reported08917
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Part 1: Lenvatinib +Pembrolizumab + ChemotherapyPart 2: Lenvatinib + Pembrolizumab + ChemotherapyPart 2: ChemotherapyTotal
American Indian or Alaska Native0111526
Asian4164161329
Native Hawaiian or Other Pacific Islander0000
Black or African American0112
White11235223469
More than one race0303666
Unknown or Not Reported0213
Geographic Region of Enrolling Site
Geographic Region of Enrolling Site(Participants)Part 1: Lenvatinib +Pembrolizumab + ChemotherapyPart 2: Lenvatinib + Pembrolizumab + ChemotherapyPart 2: ChemotherapyTotal
East Asia4161160325
North America + Western Europe5125122252
Rest of the World6157155318
Eastern Cooperative Oncology Group (ECOG) Performance Status
Eastern Cooperative Oncology Group (ECOG) Performance Status(Participants)Part 1: Lenvatinib +Pembrolizumab + ChemotherapyPart 2: Lenvatinib + Pembrolizumab + ChemotherapyPart 2: ChemotherapyTotal
ECOG 011204204419
ECOG 14239233476
Intended Chemotherapy
Intended Chemotherapy(Participants)Part 1: Lenvatinib +Pembrolizumab + ChemotherapyPart 2: Lenvatinib + Pembrolizumab + ChemotherapyPart 2: ChemotherapyTotal
CAPOX7232225464
mFOLFOX68209204421
Missing02810
08

Study locations

177 sites
  • UCLA Hematology/Oncology - Santa Monica ( Site 0003)
    Los Angeles, California 90404, United States
  • Georgetown University Medical Center ( Site 0009)
    Washington D.C., District of Columbia 20007, United States
  • James Graham Brown Cancer Center ( Site 0017)
    Louisville, Kentucky 40202, United States
  • Johns Hopkins University ( Site 0052)
    Baltimore, Maryland 21224, United States
  • Dana Farber Cancer Center ( Site 0019)
    Boston, Massachusetts 02215, United States
  • UMASS Memorial Medical Center ( Site 0020)
    Worcester, Massachusetts 01655, United States
  • Henry Ford Health System ( Site 0023)
    Detroit, Michigan 48202, United States
  • Cancer and Hematology Centers of Western Michigan ( Site 0025)
    Grand Rapids, Michigan 49503, United States
  • Washington University School of Medicine ( Site 0027)
    St Louis, Missouri 63110, United States
  • Mount Sinai Hospital ( Site 0051)
    New York, New York 10029, United States
  • Memorial Sloan Kettering Cancer Center ( Site 0032)
    New York, New York 10065, United States
  • AHN West Penn Hospital-AHN Esophageal and Lung Institute ( Site 0058)
    Pittsburgh, Pennsylvania 15224, United States
  • IDIM Instituto de Diagnostico e Investigaciones Metabolicas ( Site 0202)
    Caba, Buenos Aires C1012AAR, Argentina
  • Instituto Medico Alexander Fleming ( Site 0208)
    Ciudad Autonoma de Buenos Aires, Buenos Aires C1426ANZ, Argentina
  • Fundacion Favaloro ( Site 0201)
    Buenos Aires, C1093AAS, Argentina
  • Hospital Aleman ( Site 0210)
    Buenos Aires, C1118AAT, Argentina
  • Hospital Municipal de Gastroenterologia Dr. Bonorino Udaondo ( Site 0207)
    Buenos Aires, C1264AAA, Argentina
  • CEMIC ( Site 0209)
    Buenos Aires, C1431FWO, Argentina
  • Hospital Privado de Cordoba ( Site 0204)
    Córdoba, X5016KEH, Argentina
  • Nepean Hospital ( Site 2305)
    Kingswood, New South Wales 2747, Australia
  • Wollongong Hospital ( Site 2307)
    Wollongong, New South Wales 2500, Australia
  • Royal Brisbane and Women s Hospital ( Site 2304)
    Herston, Queensland 4029, Australia
  • Hollywood Private Hospital-Medical Oncology ( Site 2308)
    Nedlands, Western Australia 6009, Australia
  • CHU UCL Namur Site de Godinne ( Site 1005)
    Yvoir, Namur 5530, Belgium
  • UZ Gent ( Site 1002)
    Ghent, Oost-Vlaanderen 9000, Belgium
  • UZ Leuven ( Site 1004)
    Leuven, Vlaams-Brabant 3000, Belgium
  • AZ Delta ( Site 1006)
    Roeselare, West-Vlaanderen 8800, Belgium
  • Queen Elizabeth II Health Sciences Centre ( Site 0101)
    Halifax, Nova Scotia B3H 2Y9, Canada
  • Hamilton Health Sciences - Juravinski Site ( Site 0106)
    Hamilton, Ontario L8V 5C2, Canada
  • CIUSSS de l Estrie - CHUS - Centre Hosp. Univ. Sherbrooke ( Site 0103)
    Sherbrooke, Quebec J1H 5N4, Canada
  • Centro Investigación del Cáncer James Lind ( Site 0414)
    Temuco, Araucania Temuco, Chile
  • IC La Serena Research ( Site 0410)
    La Serena, Coquimbo Region 1720430, Chile
  • Clinica Universidad Catolica del Maule ( Site 0411)
    Talca, Maule Region 3460000, Chile
  • Fundacion Arturo Lopez Perez FALP ( Site 0403)
    Santiago, Region M. de Santiago 7500836, Chile
  • Clínica San Carlos de Apoquindo Red Salud UC Christus ( Site 0407)
    Santiago, Region M. de Santiago 7550000, Chile
  • Bradfordhill ( Site 0404)
    Santiago, Region M. de Santiago 8420383, Chile
  • Anhui Provincial Hospital ( Site 2415)
    Hefei, Anhui 230001, China
  • Cancer Hospital Chinese Academy of Medical Sciences ( Site 2403)
    Beijing, Beijing Municipality 100021, China
  • Beijing Cancer Hospital ( Site 2453)
    Beijing, Beijing Municipality 100035, China
  • Fujian Provincial Cancer Hospital ( Site 2408)
    Fuzhou, Fujian 350014, China
  • The 900th Hospital of the Joint Logistics Support Force of the Chinese People's Liberation Army ( Si
    Fuzhou, Fujian 350025, China
  • The First Affiliated Hospital of Xiamen University ( Site 2420)
    Xiamen, Fujian 361003, China
  • The First Affiliated Hospital of Xiamen University ( Site 2446)
    Xiamen, Fujian 361003, China
  • Zhongshan Hospital Affiliated to Xiamen University ( Site 2421)
    Xiamen, Fujian 361004, China
  • First Hospital of Lanzhou University ( Site 2417)
    Lanzhou, Gansu 730000, China
  • Nanfang Hospital ( Site 2456)
    Guangzhou, Guangdong 510000, China
  • The Affiliated Hospital Of Hainan Medical University-Cancer rehabilitation and palliative treatment
    Haikou, Hainan 570102, China
  • Fourth Hospital Of Hebei Medical University ( Site 2441)
    Shijiazhuang, Hebei 050011, China
  • Harbin Medical University Cancer Hospital ( Site 2410)
    Harbin, Heilongjiang 150081, China
  • Henan Cancer Hospital ( Site 2443)
    Zhengzhou, Henan 450008, China
  • Hubei Cancer Hospital ( Site 2429)
    Wuhan, Hubei 430079, China
  • Hunan Cancer Hospital ( Site 2440)
    Changsha, Hunan 410006, China
  • Changzhou Cancer Hospital-Department of Oncology ( Site 2458)
    Changzhou, Jiangsu 213000, China
  • Nanjing Drum Tower Hospital ( Site 2419)
    Nanjing, Jiangsu 210008, China
  • Nantong Tumor Hospital-Digestive Oncology ( Site 2464)
    Nantong, Jiangsu 226361, China
  • Jilin Cancer Hospital ( Site 2438)
    Changchun, Jilin 130012, China
  • Tang Du Hospital ( Site 2432)
    Xi'an, Shaanxi 710038, China
  • LinYi Cancer Hospital-Gastrology department ( Site 2463)
    Linyi, Shandong 276000, China
  • Shanghai General Hospital ( Site 2424)
    Shanghai, Shanghai Municipality 200080, China
  • Shanghai East Hospital ( Site 2455)
    Shanghai, Shanghai Municipality 200120, China
  • Tianjin Medical University Cancer Institute & Hospital ( Site 2447)
    Tianjin, Tianjin Municipality 300060, China
  • Cancer Hospital Affiliated to Xinjiang Medical University ( Site 2428)
    Ürümqi, Xinjiang 830011, China
  • The First Affiliated Hospital of Zhejiang University ( Site 2414)
    Hangzhou, Zhejiang 310009, China
  • Sir Run Run Shaw Hospital ( Site 2412)
    Hangzhou, Zhejiang 310016, China
  • Clinica de la Costa S.A.S. ( Site 0502)
    Barranquilla, Atlántico 080020, Colombia
  • Clinica Colsanitas S.A. Sede Clinica Universitaria Colombia ( Site 0501)
    Bogotá, Bogota D.C. 111321, Colombia
  • Sociedad de Oncología Y Hematología del Cesar S.A.S. ( Site 0508)
    Valledupar, Cesar Department 200001, Colombia
  • Oncomedica S.A. ( Site 0507)
    Montería, Departamento de Córdoba 230002, Colombia
  • Instituto Cancerologico de Narino Ltda ( Site 0504)
    Pasto, Departamento de Nariño 520001, Colombia
  • Oncologos del Occidente S.A. ( Site 0525)
    Pereira, Risaralda Department 660001, Colombia
  • CIMCA-Hemato-Oncology ( Site 0601)
    San José, Provincia de San José 10103, Costa Rica
  • Hospital Metropolitano - Sede Lindora-Metropolitano Research Institute Sede Lindora ( Site 0602)
    Santa Ana, Provincia de San José 10903, Costa Rica
  • Hôpital Edouard Herriot ( Site 1116)
    Lyon, Auvergne-Rhône-Alpes 69003, France
  • Centre Francois Baclesse ( Site 1107)
    Caen, Calvados 14076, France
  • Centre Georges Francois Leclerc ( Site 1106)
    Dijon, Cote-d Or 21079, France
  • CHU Bordeaux Haut-Leveque ( Site 1110)
    Pessac, Gironde 33604, France
  • Centre Hospitalier Annecy Genevois ( Site 1117)
    Epagny Metz-Tessy, Haute-Savoie 74370, France
  • CHU Hotel Dieu Nantes ( Site 1101)
    Nantes, Pays de la Loire Region 44093, France
  • Hopital Henri Mondor ( Site 1105)
    Créteil, Val-de-Marne 94010, France
  • Institut du Cancer Avignon-Provence ( Site 1103)
    Avignon, Vaucluse 84918, France
  • Hopital Saint Louis ( Site 1100)
    Paris, 75010, France
  • CHU Hopital Saint Antoine ( Site 1102)
    Paris, 75012, France
  • Klinikum Rechts der Isar der TU Muenchen ( Site 1200)
    Muechen, Bavaria 81675, Germany
  • Universitaetsklinikum Regensburg ( Site 1203)
    Regensburg, Bavaria 93053, Germany
  • Krankenhaus Nordwest ( Site 1205)
    Frankfurt am Main, Hesse 60488, Germany
  • Medizinische Hochschule Hannover ( Site 1210)
    Hanover, Lower Saxony 30625, Germany
  • Universitaetsklinikum Leipzig ( Site 1211)
    Leipzig, Saxony 04103, Germany
  • Charite Berlin Campus Virchow-Klinikum ( Site 1202)
    Berlin, 13353, Germany
  • Facharztzentrum Eppendorf ( Site 1201)
    Hamburg, 20249, Germany
  • Clinica Privada Dr Rixci Ramirez Fallas ( Site 0702)
    Guatemala City, 01010, Guatemala
  • Oncologika S.A. ( Site 0704)
    Guatemala City, 01010, Guatemala
  • Oncomedica ( Site 0701)
    Guatemala City, 01010, Guatemala
  • Soluciones Gastrointestinales S.A. ( Site 0706)
    Guatemala City, 01010, Guatemala
  • Sanatorio Nuestra Senora del Pilar ( Site 0705)
    Guatemala City, 01015, Guatemala
  • Medi-K Cayala ( Site 0700)
    Guatemala City, 01016, Guatemala
  • Prince of Wales Hospital ( Site 2503)
    Hong Kong, Hong Kong
  • Princess Margaret Hospital. ( Site 2502)
    Hong Kong, Hong Kong
  • Queen Mary Hospital ( Site 2501)
    Hong Kong, Hong Kong
  • St James Hospital ( Site 1400)
    Dublin, Leinster Dublin 8, Ireland
  • Beaumont Hospital ( Site 1402)
    Dublin, Dublin 9, Ireland

Showing the first 100 of 177 sites across 24 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Shitara K, Lorenzen S, Li J, Bai Y, Fernandez MG, Aguilar M, Shoji H, Reyes-Cosmelli F, Pena YR, Corrales L, Wyrwicz L, Eyzaguirre DA, Pan Y, Ryu MH, Cohen DJ, Wainberg ZA, Ku G, Tabernero J, Van Cutsem E, Qin SK, Oh DY, Xu J, Liang LW, Bordia S, Bhagia P, Rha SY; LEAP-015 Investigators. Lenvatinib Plus Pembrolizumab and Chemotherapy Versus Chemotherapy in Advanced Metastatic Gastroesophageal Adenocarcinoma: The Phase III, Randomized LEAP-015 Study. J Clin Oncol. 2025 Aug;43(22):2502-2514. doi: 10.1200/JCO-25-00748. Epub 2025 May 31. PubMed 40448579 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — https://trialstransparency.msdclinicaltrials.com/pdf/ProcedureAccessClinicalTrialData.pdf

Data sharing details ↗ · externaldatasharing-msd.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Dec 2020 to primary completion in Oct 2024, 45 months.

Results were first posted in Nov 2025, 1 year after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 4, 2020
First posted
Dec 10, 2020
StartActual
Dec 30, 2020
Primary completionActual
Oct 29, 2024
CompletionActual
Mar 30, 2026
Results first posted
Nov 28, 2025
Last update
Apr 28, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 28, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04662710
Collaborators
Eisai Inc.
Responsible party
Sponsor
First posted
Dec 10, 2020
Start date
Dec 30, 2020
Primary completion
Oct 29, 2024
Completion
Mar 30, 2026
Results posted
Nov 28, 2025
Last update
Apr 28, 2026

Study contacts

Medical Director
study director · Merck Sharp & Dohme LLC

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Pembrolizumab · Lenvatinib

Start the discussion